Testing effectiveness (Phase 2)WithdrawnNCT04982289
What this trial is testing
Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis
Who this might be right for
Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.